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Published data suggests that wedge resection for stage I non-small cell lung cancer
(NSCLC) is associated with improved overall survival compared to stereotactic body radia-
tion therapy. We report CyberKnife outcomes for high-risk surgical patients with biopsy-
proven stage I NSCLC. PET/CT imaging was completed for staging. Three-to-ﬁve gold
ﬁducial markers were implanted in or near tumors to serve as targeting references. Gross
tumor volumes (GTVs) were contoured using lung windows; the margins were expanded
by 5mm to establish the planning treatment volume (PTV).Treatment plans were designed
using a mean of 156 pencil beams. Doses delivered to the PTV ranged from 42 to 60Gy in
three fractions.The 30Gy isodose contour extended at least 1cm from the GTV to erad-
icate microscopic disease. Treatments were delivered using the CyberKnife system with
tumor tracking. Examination and PET/CT imaging occurred at 3month follow-up intervals.
Forty patients (median age 76) with a median maximum tumor diameter of 2.6cm (range,
1.4–5.0cm) and a mean post-bronchodilator percent predicted forced expiratory volume
in 1s (FEV1) of 57% (range, 21–111%) were treated. A median dose of 48Gy was deliv-
ered to the PTV over 3–13days (median, 7days). The 30Gy isodose contour extended a
mean 1.9cm from the GTV. At a median 44months (range, 12–72months) follow-up, the
3year Kaplan–Meier locoregional control and overall survival estimates compare favorably
with contemporary wedge resection outcomes at 91 and 75%, respectively. CyberKnife
is an effective treatment approach for stage I NSCLC that is similar to wedge resection,
eradicating tumors with 1–2cm margins in order to preserve lung function. Prospective
randomized trials comparing CyberKnife with wedge resection are necessary to conﬁrm
equivalence.
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INTRODUCTION
Standard therapy for operable stage I non-small cell lung can-
cer (NSCLC) is lobectomy (Ginsberg and Rubinstein, 1995). This
surgery requires the complete removal of the involved lobe plus
ipsilateral hilar and mediastinal lymph node dissection. Conse-
quently, locoregional recurrence is uncommon following lobec-
tomy. Unfortunately, lobectomy is a major operation often asso-
ciated with clinically meaningful declines in pulmonary function
(Ginsberg and Rubinstein,1995),multiple potentially debilitating
morbidities (Handy et al., 2002), and infrequently death (Allen
et al., 2006). Sublobar resection (segmentectomy or wedge resec-
tion) with adequate margins (1–2cm) or adjuvant brachytherapy
has been advocated for high-risk surgical patients with small
peripheral lesions (Narsule et al.,2011). Such treatment in appro-
priately selected patients provides acceptable locoregional control
without the early mortality and potentially clinically meaningful
decline in lung function associated with lobectomy (Lee et al.,
2003; Santos et al.,2003).
Historically, treatment outcomes for inoperable patients with
clinical stage I NSCLC have been poor (Qiao et al., 2003). Both
locoregional control and survival are typically disappointing with
conventional radiation therapy techniques. For example, a study
of conventionally fractionated radiation therapy studies found
locoregional control rates ranging from 30 to 81% and a mean
5year overall survival rate of 21% (Qiao et al., 2003). The devel-
opment of stereotactic body radiation therapy (SBRT), capable
of treating lung tumors with tight margins (1cm), has improved
outcomes (Lax et al.,2006). SBRT trials,utilizing adequate tumor
doses, have consistently reported locoregional control rates com-
parable to surgery with locoregional control rates ranging from
78 to 87% and 3year overall survival rates of 55–88% (Timmer-
man et al., 2003, 2006; Onishi et al., 2004; Mcgarry et al., 2005).
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Nonetheless, recently reported overall survival rates for high-risk
surgical patients remain poor with such techniques (Grills et al.,
2010; Timmerman et al., 2010). This poor survival has for the
most part been attributed to comorbid illness rather than lung
cancer progression; treatment related lung damage has not been
implicated as a cause of mortality in these patients as initially
predicted despite the generally high-lung doses delivered and the
severe baseline pulmonary dysfunction reported.
We began treating stage I NSCLC patients in late 2004 using
the CyberKnife® frameless robotic radiosurgery system (Accu-
ray Incorporated, Sunnyvale, CA, USA) with Synchrony® tumor
tracking using ﬁducials (Collins et al., 2007, 2009) .T h eg o a lo f
such treatment was to maintain the impressive locoregional con-
trolratesof SBRTwhilefurtherdecreasingradiationinducedlung
damage and potentially improving survival. Continuous tracking
of respiratory tumor motion and highly accurate beam alignment
throughout treatment with the CyberKnife allowed us to deliver
dosedistributionswithtightermarginsonthegrosstumorvolume
(GTV) than historically feasible (5mm; Hoogeman et al., 2009).
Numerous pencil beams were used to produce dose gradients that
conformcloselytotheshapeof thetarget,resultingintheoretically
adequate microscopic disease doses extending 1cm or more from
the tumor (Papiez et al., 2003). The goal was similar to that of
wedge resection, i.e., to reliably eradicate tumors with the mini-
mumnecessarymargintopreservelungfunction(Goldsteinetal.,
2003). We report intermediate outcomes for 40 consecutive high-
risksurgicalpatientswithclinicalstageINSCLCtreatedusingthis
novel treatment approach at Georgetown University Hospital.
MATERIALS AND METHODS
ELIGIBILITY
The Medstar Health Research Institute – Georgetown University
Oncology institutional review board approved this study and all
participants provided informed written consent. The multidis-
ciplinary thoracic oncology team evaluated patients. High-risk
surgical patients with pathologically conﬁrmed clinical Stage I
NSCLC measuring 5cm or less in maximum diameter were con-
sidered for protocol treatment. High-risk was deﬁned as a post-
bronchodilator percent predicted forced expiratory volume in 1s
(FEV1) of less than 50%, a carbon monoxide diffusing capacity
(DLCO) of less than 50%, age greater than 75, or severe comor-
bid medical conditions. Prior to treatment, CT imaging of the
chest and abdomen with IV contrast, PET imaging, and routine
pulmonary function tests (PFTs) were completed when feasible.
Mediastinoscopy was not performed for staging. Candidates were
excluded from protocol treatment if ﬁducials could not be safely
placedfortumortrackingorpredeterminedcriticalstructuremax-
imum radiation point dose limits could not be adhered to during
treatment planning (Table 1).
FIDUCIAL PLACEMENT
With conscious sedation and local anesthesia, three to ﬁve gold
ﬁducials measuring 0.8–1mm in diameter by 3–7mm in length
(Item351-1BestMedicalInternationalInc.,Springﬁeld,VA,USA)
were placed with adequate spacing (1–2cm) in or near tumors
under CT-guidance as previously described (Banovac et al., 2007;
Youseﬁ et al., 2007).
T a b l e1|C r itical structure radiation dose limits.
Adjacent structure Maximum dose limit
(total for three fractions; Gy)
Spinal cord 18
Esophagus 27
Heart 30
Main bronchus 30
Trachea 30
Great vessels 40
TREATMENT PLANNING
Fine-cut (1.25mm) treatment planning CTs were obtained 7–
10days after ﬁducial placement during a full inhalation breath-
hold. GTVs were contoured utilizing lung windows. The GTV
margin was expanded 5mm to establish the planning treatment
volume (PTV). All critical central thoracic structures (Table 1)
and the lungs were contoured to ensure that incidental radiation
delivered to these structures was limited. A treatment plan was
generated using the CyberKnife non-isocentric, inverse-planning
ray-tracing algorithm with tissue density heterogeneity correc-
tions for lung. Lower doses within the range of 42–60Gy in three
fractions were prescribed when concerns about adjacent critical
structures arose and when patients were felt to have severe pul-
monary dysfunction. The radiation was delivered to an isodose
line that covered at least 95% of the PTV and resulted in the 30Gy
isodose contour extending a minimum of 1cm from the GTV. As
described in detail elsewhere (Collins et al., 2009), this approach
is similar to sublobar resection which eliminates the tumor with
1cm or greater margin to ensure that microscopic tumor exten-
sion is effectively treated. The percentage of the total lung volume
receiving 15Gy or more (V15) was limited to 15%.
TREATMENT DELIVERY
PatientsweretreatedaccordingtotheGeorgetownUniversityHos-
pital small peripheral pulmonary nodule protocol as previously
described(Collinsetal.,2007).Brieﬂy,patientswerebroughttothe
CyberKnife suite and laid supine on the treatment table with their
arms at their side. Three red light-emitting diodes (LEDs) were
placed on the patient’s anterior torso directed toward the camera
array. Fiducials were located using orthogonal X-ray imagers. A
correlation model was created between the LEDs tracked contin-
uously by the camera array and ﬁducial positions imaged peri-
odically by the X-ray targeting system. During treatment delivery
the tumor position was tracked using the live camera array sig-
nal and correlation model; the linear accelerator was moved by
the robotic arm to maintain precise alignment with the tumor
throughout the respiratory cycle during radiation delivery. Fidu-
cialswereimagedpriortothedeliveryofeverythirdbeamtoverify
targeting accuracy and to update the correlation model.
FOLLOW-UP STUDIES
Examination and PET/CT imaging were performed at 3month
follow-up intervals. Locoregional recurrence was deﬁned as pro-
gression in the involved lobe or regional lymph nodes per serial
PET/CT imaging as previously reported (Vahdat et al., 2010).
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Other failures were considered distant. Biopsy was required to
conﬁrm progression.
STATISTICAL ANALYSIS
Data was analyzed and graphs were prepared with the SPSS 16.02
statistical package (IBM Corporation, Armonk, NY, USA). The
follow-up duration was deﬁned as the time from the date of com-
pletionofCyberKnifetreatmenttothelastdateoffollow-uporthe
date of death. Actuarial locoregional control and overall survival
were calculated using the Kaplan–Meier method.
RESULTS
PATIENT AND TUMOR CHARACTERISTICS
Forty consecutive patients (16 men and 24 women) with clinical
stage I NSCLC (19 adenocarcinoma,12 squamous cell carcinoma,
and9nototherwisespeciﬁedNSCLC)andanEasternCooperative
Oncology Group (ECOG) performance status of two or less were
treated over a 60month period extending from November 2004
to 2009 (Table 2). No patients were lost to follow-up. Ninety-
ﬁve percent of the patients were smokers; pulmonary dysfunction
was the primary rationale for non-surgical treatment. The mean
post-bronchodilator percent predicted FEV1 was 57% (range,21–
111%). The mean maximum tumor diameter was 2.87cm (range,
1.40–5.00cm).
TREATMENT CHARACTERISTICS
Treatment plans were composed of a mean of 156 pencil beams
(Table 3). A median dose of 48Gy was delivered to the prescrip-
tion isodose line in three 1–2h treatments over a 5–11day period
(mean, 7days). The 30Gy isodose contour, equivalent to 50Gy in
25 fractions (Barton, 1995), extended a mean distance of 1.9cm
fromtheGTVtotreatmicroscopicdisease.Thepercentofthetotal
lungvolumereceiving15Gyormorewas6.4%(range,2.2–13.6%).
No patient received adjuvant chemotherapy.
DISEASE SPREAD AND SURVIVAL
All patients with persistent tumor SUVmax elevations following
treatment were biopsied. Two local, one regional, and six dis-
tant failures were pathologically conﬁrmed during follow-up.At a
median follow-up of 44months (range,12–72months),the 3year
Kaplan–Meier locoregional control and overall survival estimates
were 91 and 75%,respectively (Figures1 and 2). Ten of 12 deaths
were attributed to pulmonary dysfunction. Two patients devel-
oped progressive metastatic disease which resulted in their death
during the third follow-up year.
DISCUSSION
Grills et al. (2010) published the results of an institutional ret-
rospective analysis comparing SBRT with wedge resection for
high-risk surgical patients with stage I NSCLC. This study was
valuable because it was the ﬁrst study to compare current SBRT
and wedge resection outcomes. Increasingly, high-risk surgical
patientsareconsideringtheseoptionswithminimaldataavailable
to aide decision-making. Although treatment arms were not ran-
domized, known prognostic factors were similar but consistently
inferior for the SBRT group. The primary ﬁnding of the Grills
study was that locoregional control at 30months was improved
T a b l e2|P atient and tumor characteristics.
FEV1, L
Mean 1.22
Range 0.53–3.06
PREDICTED FEV1 (%)
Mean 57
Range 21–111
DLCO (mL/min/mmHg)
Mean 9.99
Range 3.49–23.30
MEAN % PREDICTED DLCO
Mean 55
Range 14–128
ECOG
Median 1
Range 0–2
AGE (YEARS)
Median 76
Range 63–87
SEX (%)
Male 40
Female 60
RACE (%)
Caucasian 82.5
African 17 .5
SMOKER (%)
Yes 95
No 5
HISTOLOGY (%)
Adenocarcinoma 48
Squamous cell carcinoma 30
NSCLC NOS 22
CLINICAL STAGE (%)
T1N0 60
T2N0 40
MAXIMUM DIAMETER (cm)
Mean 2.87
Median 2.60
Range 1.40–5.00
Table 3 |Treatment characteristics.
Mean (range)
Prescribed dose (Gy) in three treatments 50 (42–60)
Prescription isodose line (%) 80 (74–85)
30Gy isodose contour mean distance from the GTV (cm) 1.90 (1.08–2.74)
Number of beams per treatment 156 (79–242)
Number of paired X-ray veriﬁcation images per treatment 52 (26–81)
Treatment course (days) 7 (5–11)
%Total lung volume receiving 15Gy or more 6.4 (2.2–13.6)
with SBRT (91 vs. 73%) and therefore SBRT was a reasonable
treatment option for high-risk surgical patients not eligible for
anatomic lobectomy. However, the validity of this conclusion has
been questioned. Overall survival at 30months was statistically
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FIGURE 1 | Kaplan–Meier plot of locoregional control.
FIGURE 2 | Kaplan–Meier plot of overall survival.
inferior in the SBRT group (72 vs. 87%) conceivably enhancing
SBRT’s locoregional control.
In late 2004, we initiated a CyberKnife protocol for high-risk
surgical patients with stage I NSCLC. Forty patients were treated
in 60months and followed for a minimum of 1year. The goal
was similar to that of wedge resection, i.e., to reliably eradicate
tumors with the minimum necessary margin to preserve lung
function. In the absence of comparative wedge resection results
from our institution, we discuss the Grills et al. wedge resection
outcomes here with respect to our outcomes.While a quantitative
analysis has not been performed, the limited availability of data
comparing SBRT to wedge resection and the desire for alternative
treatment approaches for this high-risk surgical patient popula-
tion compel us to explore the differences and similarities in these
outcomes.
Baseline prognostic characteristics for the CyberKnife cohort
were similar but generally inferior to the Grills et al. (2010) wedge
resectioncohort.However,theinvasiveﬁducialplacementrequire-
mentforCyberKnifetreatmentprecludedthesickestpatientsfrom
protocol therapy likely enhancing overall survival compared to
the Grills et al. (2010) SBRT cohort. The 3year locoregional con-
trol and overall survival estimates are comparable to the William
BeaumontHospitalwedgeresectioncohortat91and75%,respec-
tively(Grillsetal.,2010).Baseduponapproximatevaluesobtained
from the survival curves reported by Grills et al.,we conclude that
CyberKnife treatment with tumor tracking results in locoregional
control (91 vs. ∼70%) and overall survival similar to wedge resec-
tion (75 vs. ∼80%) for high-risk surgical patients with clinical
stage I NSCLC. Both CyberKnife and wedge resection are reason-
able treatment options for high-risk surgical patients not eligible
for segmentectomy or lobectomy.
Critical issues concerning the validity of our observations do
exist.ItiswidelyheldthatPET/CTimagingsurveillancepromptly
identiﬁes locoregional recurrence following wedge resection.
However, high peritumoral lung doses often result in focal radia-
tioninducedpneumonitisandﬁbrosis,hamperingPET/CTrecur-
rence assessment following irradiation (Vahdat et al., 2010). Rou-
tine biopsy was not completed in our cohort given the uncertain
clinical signiﬁcance of early transient elevations in tumor SUVmax
following radiation treatment and the risk associated with biopsy
in this high-risk surgical patient population with limited sal-
vage treatment options. Therefore, conﬁrmation of radiographic
impressions was limited to biopsy in three patients following a
persistent increase in tumor SUVmax; biopsies were not taken to
conﬁrm the absence of disease in cases in which tumor SUVmax
remained low or returned to the normal range following tran-
sient elevations. Therefore, it is likely that the CyberKnife 3year
locoregional control rate is less than our reported 91% rate.
Finally,theGrillsetal.wedgepatientsdiscussedhereareclearly
biased against wedge resection. This group was retrospectively
collected from the general patient population of the William
Beaumont Hospital while the CyberKnife patients were selected
for protocol therapy from the high-risk surgical patient popula-
tion treated at Georgetown University Hospital. Unfortunately,to
our knowledge, no contemporary single institution prospective
wedge resection outcomes data exists. Ultimately, the results of
randomized trials will dictate treatment recommendations. In the
interim, we will continue to treat selected consenting high-risk
surgical patients with clinical stage I NSCLC using CyberKnife
if wedge resection is the only surgical treatment option. The
present encouraging intermediate outcomes adequately support
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this practice in this frail patient population that characteristically
dies of comorbid illnesses rather than tumor progression.
CONCLUSION
CyberKnife is an effective treatment for stage I NSCLC. The
approach is similar to that of wedge resection,eradicating tumors
with 1–2cm margins in order to preserve lung function. Locore-
gional control and overall survival outcomes appear similar to
contemporary wedge resection results. Prospective randomized
trials comparing CyberKnife with wedge resection for high-risk
surgical patients with stage I NSCLC are necessary to conﬁrm
equivalence.
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